Literature DB >> 23690219

Expression of CD200 and CD200R regulatory molecules on the CD83+ monocyte-derived dendritic cells generated from patients with laryngeal cancer.

Janusz Klatka1, Ewelina Grywalska, Maria Klatka, Mansur Rahnama, Agnieszka Polak, Jacek Rolinski.   

Abstract

CD200 molecule may play a role in local tumor invasion and augmenting the metastatic capacity of squamous cell carcinoma. The objective of the study was to assess by means of flow cytometry the expression of CD200 and its receptor, CD200R, on CD83+ monocyte-derived dendritic cells (Mo-DCs), pulsed or not with autologous tumor cell lysates (aTCL) in patients who suffer from laryngeal carcinoma in comparison to healthy donors. The median value of CD200 mean fluorescence intensity (MFI) on the Mo-DCs pulsed with aTCL of the patients with laryngeal cancer was 61.94 and was statistically significantly higher than on the unpulsed Mo-DCs of these patients (24.81) and healthy donors (16.63), p = 0.0034 and p = 0.0004, respectively. Median MFI score of CD200R in specimen derived from patients with laryngeal cancer was 259.31 on Mo-DCs pulsed with aTCL, while in unpulsed Mo-DCs was 86.74 (p = 0.0035) and on the Mo-DCs from control group it was 67.51 (p = 0.0004). The obtained results showed a relation between the presence of laryngeal cancer and the expression of CD200 and CD200R molecules on the CD83+ Mo-DCs pulsed with autologous cancer cell lysates. This analysis may have implications for setting new therapeutic options for cancer immunotherapy in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690219     DOI: 10.5603/FHC.2013.009

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  1 in total

1.  Subpopulations of natural killer-T-like cells before and after surgical treatment of laryngeal cancer.

Authors:  Janusz Klatka; Ewelina Grywalska; Anna Hymos; Ewelina Krasowska; Michał Mielnik; Dorota Siwicka-Gieroba; Justyna Markowicz; Piotr Trojanowski; Witold Olszański; Jacek Roliński
Journal:  Cent Eur J Immunol       Date:  2017-10-30       Impact factor: 2.085

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.